Studies have demonstrated that MTE administration could restore the gefitinib sensitivity in gefitinib-resistant NSCLC cells H460 and H1975 in vivo and in vitro through downregulating the ERK1/2, c-Met, and PI3K/AKT/mTOR pathways (19, 20). This evidence concerns the gene MET and non-small cell lung carcinoma.